F. Hoffmann-La Roche Ltd: CHMP recommends EU approval of Roc

Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large B-cell lymphoma (DLBCL) over the standard of care in more

Related Keywords

Portugal , Japan , Lugano , Ticino , Switzerland , United States , France , Belgium , America , Nathalie Meetz , Polatuzumab Vedotin , Karl Mahler , Sabine Borngr , Gerard Tobin , Bruno Eschli , Birgit Masjost , Sileia Urech , Loren Kalm , Karsten Kleine , Genentech , Lymphoma Study Association , World Health Organization , Roche Group , Roche Group Media Relations , Lymphoma Academic Research Organisation , Lugano Response Criteria , Dow Jones Sustainability Indices , Chugai Pharmaceutical , Cancer Incidence , Previously Untreated Diffuse Largeb Cell , Hoffmann , Oche , Thmp , Ecommends , Approval , Polivy , Combination , People , Reviously , Untreated , Diffuse , Barge , Fell , Lymphoma ,